Related Experiment Video
Updated: Nov 5, 2025

Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats
Published on: January 21, 2020
What's new in chronic pain pathophysiology
1Department of Anesthesiology, Jacobs School of Medicine, SUNY University at Buffalo and Biomedical Sciences, Buffalo, New York, USA.
Abstract:
The understanding of pain pathophysiology is continuously evolving. Identifying underlying cellular and subcellular pathways helps create opportunities for targeted therapies that may prove to be effective interventions. This article is an update on four areas of developing knowledge as it pertains to clinical management of patients with pain: nerve growth factor antagonists, microglial modulation, AMP-activated protein kinase activators, and genetic pain factors. Each of these areas represents novel targets for targeted therapies to prevent, treat, and modify the disease course of acute, chronic, and neuropathic pain. Currently most pain management techniques do not target these pathways directly, but there is promising evidence to suggest that the field is advancing toward available therapies in the near future.
Insights
New pain management strategies are emerging, focusing on nerve growth factor antagonists, microglial modulation, AMP-activated protein kinase activators, and genetic pain factors for targeted therapies.
Area of Science:
- Pain research
- Neuroscience
- Pharmacology
Background:
- Pain pathophysiology understanding is evolving.
- Cellular and subcellular pathways offer targeted therapy opportunities.
- Current pain management often lacks direct pathway targeting.
Purpose of the Study:
- To update knowledge on four developing areas in pain management.
- To highlight novel targets for preventing, treating, and modifying pain.
- To bridge current practices with future therapeutic advancements.
Main Methods:
- Review of emerging research in nerve growth factor antagonists.
- Analysis of microglial modulation strategies.
- Exploration of AMP-activated protein kinase activators.
- Investigation of genetic pain factors.
Main Results:
- Nerve growth factor antagonists show therapeutic potential.
- Microglial modulation offers new avenues for pain control.
- AMP-activated protein kinase activators present novel treatment options.
- Genetic factors are increasingly recognized in pain conditions.
Conclusions:
- These four areas represent novel targets for targeted pain therapies.
- Advancements suggest future availability of therapies targeting these pathways.
- The field is progressing towards effective interventions for acute, chronic, and neuropathic pain.
Related Concept Videos
Analgesia and Pain Management
Nociception
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pain
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...

